All In Biotech

Drug Trial Radar · NCT06154278

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Pilot Study to Evaluate Intrahepatic and Peripheral Responses to Small Interfering RNA, Imdusiran (AB-729), Among People With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jul 25, 2024

Primary completion

Dec 1, 2026

Study completion Jul 1, 2027

Sponsor

Lead sponsor
University of Maryland, BaltimoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arbutus Biopharma Corporation
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.

Conditions

  • Chronic Hepatitis B

Interventions

  • Imdusiran (AB-729)Drug

    60mg subcutaneously, every 8 weeks, for a total of 4 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intrahepatic concentration of Imdusiran (AB-729)Time frame: During intervention (with first dose of Imdusiran) and after intervention (8 weeks after last dose of Imdusiran)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Human Virology, University of Maryland School of Medicine

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.